Inflation Reduction Act Implementation Accelerates as Medicare Drug Price Negotiations and Executive Actions Reshape 2026 Market

The implementation of the Inflation Reduction Act (IRA) has entered a critical operational phase as the first round of negotiated Medicare drug prices took effect on January 1, 2026. This transition marks a significant shift toward federal control of pharmaceutical pricing, with the Centers for Medicare & Medicaid Services (CMS) now expanding negotiations to include Part B drugs and additional Part D therapies. For the pharmaceutical sector, these developments necessitate a strategic pivot toward compliance and operational execution following the failure of major legal challenges to block the program.

The Medicare Drug Price Negotiation Program transitioned from planning to active execution in 2026, with the initial 10 Part D drugs seeing an average discount of 63% off list prices. CMS has already initiated the third cycle of negotiations, selecting 15 additional drugs that for the first time include those payable under Medicare Part B, such as the renegotiation of Tradjenta. Manufacturers for all 15 selected drugs agreed to participate by March 2026, setting a timeline that includes initial offers in June and final price publications by November 30, 2026, with these prices slated to take effect in 2028.

Legal hurdles that once threatened the IRA's pricing provisions have largely been cleared, providing the federal government with a firm legal footing to proceed. On May 18, 2026, the Supreme Court denied six petitions for certiorari from major manufacturers, including AstraZeneca and Novartis, effectively ending the primary wave of constitutional challenges. While some litigation remains pending in the Fifth and DC Circuits, the judiciary's general refusal to block the program—based on the premise that Medicare participation is voluntary—has shifted the industry's focus from constitutional risk to the necessity of adjusting contracting and compliance systems.

Beyond the IRA, executive actions have introduced new pressures on the pharmaceutical industry regarding domestic production and international pricing alignment. The Trump administration’s 2025 Most-Favored-Nation Executive Order and subsequent threats of 100% tariffs under Section 232 of the Trade Expansion Act have pushed manufacturers to increase US-based production and invest in a Strategic API Reserve. Despite legal complexities regarding the use of emergency powers for import taxes, these policy levers are being used to force pricing concessions and accelerate the onshoring of pharmaceutical supply chains, as evidenced by the presidential proclamation issued on April 2, 2026.